

25 November 2010 EMA/HMPC/144006/2009 Committee on Herbal Medicinal Products (HMPC)



The terms of the second	Maich 2009
Discussion in working Party on Community monographs and Community	
list (MLWP)	May 2009
	July 2009
	September 2009
Adoption by Committee on Herbal Medicinal Products (HMPC) for release	
for consultation	17 September 2009
End of consultation (deadline for comments). Comments should be	
	15 February 2010
provided using this <u>template</u> to <u>hmpc.secretariat@ema.europa.eu</u>	
Rediscussion in Working Party on Community monographs and	May 2010
Community list (MLWP)	July 2010
	September 2010
	November 2010
Adoption by Committee on Herbal Medicinal Products (HMPC)	25 November 2010

Keywords	Herbal medicinal products; HMPC; Community herbal monographs; well-
	established medicinal use; traditional use; Vitex agnus-castus L.; Agni casti
	fructus; agnus castus fruit

BG (bălgarski): Аврамово дърво, плод	LT (lietuvių kalba):
CS (čeština): Drmkový plod	LV (latviešu valoda): Viteksa augļi
DA (dansk): Kyskhedstræfrugt	MT (malti): Frotta tas-Siġret il-Virgi
DE (Deutsch): Mönchspfefferfrüchte	NL (nederlands): Monnikspeper, Kuisboom
EL (elliniká): Καρπός λυγαριάς	PL (polski): Owoc niepokalanka zwyczajnego
EN (English): Agnus castus fruit	PT (português): Anho-casto, fruto
ES (espanol): Sauzgatillo, fruto de	RO (română): Fruct de scai de tufă mare
ET (eesti keel): Mungapipravili	SK (slovenčina): Plod vitexu jahňacieho
FI (suomi):	SL (slovenščina): Plod navadne konopljike
FR (français): Gattilier (fruit de)	SV (svenska): Munkpeppar, frukt
HU (magyar): Barátcserje termés	IS (íslenska):
IT (italiano): Agnocasto frutto	NO (norsk): Agnocastofrukt



Community herbal monograph on Vitex agnus-castus L., fructus

1. Name of the medicinal product

To be specified for the individual finished product.

2. Qualitative and quantitative composition 1,2

Well-established use	Traditional use
With regard to the marketing authorisation application of Article 10(a) of Directive 2001/83/EC as amended	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
Vitex agnus-castus L., fructus (agnus castus fruit)	Vitex agnus-castus L., fructus (agnus castus fruit)
i) Herbal substance	i) Herbal substance
Not applicable.	Not applicable
ii) Herbal preparations	ii) Herbal preparations
Dry extract (DER 6-12:1) , extraction solvent:	a) Powdered herbal substance
ethanol 60% m/m	b) Tincture (ratio of herbal substance to extraction solvent 1:5), extraction solvent: ethanol 58-60% V/V
	 c) Tincture (ratio of herbal substance to extraction solvent 1:5), extraction solvent: ethanol 70% V/V (manufacture under addition of calcium carbonate)
	d) Dry extract (DER 7-13:1), extraction solvent: ethanol 60% m/m
	e) Dry extract (DER 10.0-18.5:1), extraction solvent: ethanol 50-52% m/m

3. Pharmaceutical form

Well-established use	Traditional use
Herbal preparation in solid dosage form for oral use.	Herbal preparation in solid or liquid dosage forms for oral use.
The pharmaceutical form should be described by the European Pharmacopoeia full standard term.	The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

 $^{^1}$ The material complies with the Ph. Eur. monograph (01/2008:2147 corrected 6.2) 2 The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

4. Clinical particulars

4.1. Therapeutic indications

Well-established use	Traditional use
Herbal medicinal product for the treatment of premenstrual syndrome.	Traditional herbal medicinal product for the relief of minor symptoms in the days before menstruation (premenstrual syndrome). The product is a traditional herbal medicinal product for use in the specified indication exclusively based upon long-standing use.

4.2. Posology and method of administration

Well-established use	Traditional use
Posology	Posology
Adults	Adults
Daily dose:	Daily dose:
Once daily 20 mg extract equivalent to 180 mg of the herbal substance.	a) two times daily 400 mg powdered herbal substance
The use in children and adolescents under 18	b) once daily 40 drops
years of age is not recommended (see section 4.4 'Special warnings and precautions for use').	c) once daily 30-40 drops corresponding to approximately 33 mg herbal substance
Duration of use	d) once daily 4 mg dry extract corresponding
To achieve an optimal treatment effect, continued	to 28-52 mg herbal substance
use over three months is recommended.	e) once daily 2-3 mg dry extract
If the symptoms persist after a continued use over three months, a doctor should be consulted.	corresponding to 30-48 mg herbal substance
Method of administration Oral use.	The use in children and adolescents under 18 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
	Duration of use
	If the symptoms persist after a continued use over three months, a doctor or a qualified health care practitioner should be consulted.
	Method of administration
	Oral use.

4.3. Contraindications

Well-established use	Traditional use
Hypersensitivity to the active substance.	Hypersensitivity to the active substance.

4.4. Special warnings and precautions for use

Traditional use Well-established use Patients who suffer or suffered from an oestrogen-Patients who suffer or suffered from an oestrogensensitive cancer should consult their doctor before sensitive cancer should consult their doctor before using Vitex agnus-castus. using Vitex agnus-castus. Patients who are using dopamine agonists, Patients who are using dopamine agonists, dopamine antagonists, oestrogens and dopamine antagonists, oestrogens and antioestrogens should consult their doctor before antioestrogens should consult their doctor before using Vitex agnus-castus. (see section 4.5 using Vitex agnus-castus. (see section 4.5 'Interactions with other medicinal products and 'Interactions with other medicinal products and other forms of interaction') other forms of interaction') The use in children and adolescents under The use in children and adolescents under 18 years of age has not been established due to 18 years of age has not been established due to lack of adequate data. lack of adequate data. If the symptoms worsen during the use of the If the symptoms worsen during the use of the medicinal product, a doctor or a pharmacist medicinal product, a doctor or a qualified health should be consulted. care practitioner should be consulted. Vitex agnus-castus, fructus is thought to act on Vitex agnus-castus, fructus is thought to act on the pituitary-hypothalamic axis and therefore the pituitary-hypothalamic axis and therefore patients with a history of a pituitary disorder patients with a history of a pituitary disorder should consult a doctor before use. should consult a doctor before use. In cases of prolactin secreting tumours of the In cases of prolactin secreting tumours of the pituitary gland the intake of Vitex agnus-castus, pituitary gland the intake of Vitex agnus-castus, fructus can mask symptoms of the tumour. fructus can mask symptoms of the tumour. For tinctures containing ethanol, the appropriate labelling for ethanol, taken from the 'Guideline on excipients in the label and package leaflet of medicinal products for human use', must be included.

4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
Because of the possible dopaminergic and	Because of the possible dopaminergic and
oestrogenic effects of Vitex agnus-castus, fructus	oestrogenic effects of Vitex agnus-castus, fructus
interactions with dopamine agonists, dopamine	interactions with dopamine agonists, dopamine
antagonists, oestrogens and antioestrogens	antagonists, oestrogens and antioestrogens
cannot be excluded.	cannot be excluded.

4.6. Pregnancy and lactation

Well-established use	Traditional use
There is no indication for the use during pregnancy.	There is no indication for the use during pregnancy.
Data from reproductive studies suggest that extracts of <i>Vitex agnus-castus</i> , fructus may affect lactation. The use during lactation is not recommended.	Data from reproductive studies suggest that extracts of <i>Vitex agnus-castus</i> , fructus may affect lactation. The use during lactation is not recommended.

4.7. Effects on ability to drive and use machines

Well-established use	Traditional use
No studies on the effect on the ability to drive and	No studies on the effect on the ability to drive and
use machines have been performed.	use machines have been performed.

4.8. Undesirable effects

Well-established use	Traditional use
Severe allergic reactions with face swelling,	Severe allergic reactions with face swelling,
dyspnoea and swallowing difficulties. (Allergic)	dyspnoea and swallowing difficulties. (Allergic)
skin reactions (rash and urticaria), headache,	skin reactions (rash and urticaria), headache,
dizziness, gastrointestinal disorders (such as	dizziness, gastrointestinal disorders (such as
nausea, abdominal pain), acne, menstrual	nausea, abdominal pain), acne, menstrual
disorders have been reported. The frequency is	disorders have been reported. The frequency is
not known.	not known.
If other adverse reactions not mentioned above	If other adverse reactions not mentioned above
occur, a doctor or a pharmacist should be	occur, a doctor or a qualified health care
consulted.	practitioner should be consulted.

4.9. Overdose

Well-established use	Traditional use
No case of overdose has been reported.	No case of overdose has been reported.

5. Pharmacological properties

5.1. Pharmacodynamic properties

Well-established use	Traditional use
Pharmacotherapeutic group:	Not required as per Article 16c(1)(a)(iii) of
ATC code: G02CX (Other gynaecologicals)	Directive 2001/83/EC as amended.
Most preclinical pharmacological data were raised using ethanol or methanol extracts. Inhibitory influences on prolactin release and dopaminergic (dopamine-agonistic) effects were seen by different working groups.	
There are contradictory results concerning binding to estrogen receptor in general and the preferential binding to β - or α -receptors. Furthermore there are some references concerning β -endorphin-like activity (possibly via μ -opiate receptor binding).	

5.2. Pharmacokinetic properties

Well-established use	Traditional use
No data available.	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.3. Preclinical safety data

Well-established use	Traditional use
There are only limited preclinical safety data for Vitex agnus castus, fructus or preparations thereof.	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product.
Tests on mutagenicity and carcinogenicity have not been performed.	Tests on mutagenicity and carcinogenicity have not been performed.
In two repeat-dose toxicity studies signs of liver toxicity have been observed. In the 26 weeks study, effects were observed at all doses tested.	Limited data from reproductive studies suggest that extracts of <i>Vitex agnus castus</i> , fructus influence lactation.
Limited data from reproductive studies suggest that extracts of <i>Vitex agnus castus</i> , fructus	Adequate tests on reproductive toxicity have not been performed.

Well-established use	Traditional use
influence lactation.	
Adequate tests on reproductive toxicity have not been performed.	

6. Pharmaceutical particulars

Well-established use	Traditional use	
Not applicable.	Not applicable.	

7. Date of compilation/last revision

25 November 2010

